Development of CVL-231 for the Treatment of Psychosis

Time: 10:00 am
day: Day One


• CVL-231 was rationally designed as a positive allosteric modulator (PAM) that selectively targets the muscarinic acetylcholine 4 (M4) receptor subtype
• Harnessing the anti-psychotic benefit believed to be associated with M4 while minimizing the side effects typically associated with panmuscarinic agonists
• Phase 1b data readout
• Plans to further evaluate the potential of CVL-231 to provide a significant medical advancement